thasso

Blog Archives

Brodalumab (Siliq) with a fatal touch: New psoriasis drug approved

Posted on February 16, 2017 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], New Drug Approval, Thasso Post, Theragenomic Medicine 1 Comment ↓

February 16, 2017 – The American Food & Drug Administration (FDA) just approved Brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab (Siliq) is administered as an injection. Brodalumab (Siliq) is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream,

…

With Infliximab (Flixabi), a huge biosimilar medicine has been approved in the European Union (EU)

Posted on June 22, 2016 by by

thassodotcom Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

June 22, 2016 – The European Medicines Agency (EMA) has approved, as of the end of May 2016, Infliximab (Flixabi). Infliximab (Flixabi) is a monoclonal antibody that has been designed to attach to a protein called tumour necrosis factor-alpha (TNF-alpha) and block its activity.

…

Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity

Posted on May 8, 2016 by by

Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF Posted in PubMed Entry, Thasso Post, Theragenomic Medicine No Comments ↓

Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF

JAMA Dermatol 2016 Apr;

PMID: 27120802

Abstract

Importance: Psoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear.

…

Tags: Diabetes Type 2, Genetic Association, Obesity, Psoriasis, Twin Study

Theragenomic medicine: First case of fumarate-linked progressive multifocal leukoencephalopathy (PML) in nonlymphopenic patient

Posted on April 11, 2015 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Thasso Post, Theragenomic Medicine 2 Comments ↓

April 11, 2015 – Dutch clinicians report what they believe is the first case of progressive multifocal leukoencephalopathy (PML) after treatment with compounded dimethyl fumarate (DMF) in a patient without severe lymphocytopenia. This situation was “previously thought to be unlikely,” Dennis Nieuwkamp,

…

The new psoriasis drug Secukinumab (Cosentyx), a IL-17A-inhibiting antibody, approved by the FDA

Posted on January 22, 2015 by by

thassodotcom Posted in New Drug Approval, Thasso Post 3 Comments ↓

January 21, 2015 – On this day, the U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is an autoimmune disorder, and occurs more commonly in patients in with a family history of the disease,

…